Delcath Systems, Inc. (NASDAQ:DCTH) Receives Average Recommendation of “Moderate Buy” from Brokerages

Delcath Systems, Inc. (NASDAQ:DCTH) has been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $22.50.

A number of research analysts have issued reports on DCTH shares. Weiss Ratings raised shares of Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Zacks Research raised Delcath Systems from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th.

Institutional Trading of Delcath Systems

Large investors have recently added to or reduced their stakes in the company. Millennium Management LLC raised its stake in shares of Delcath Systems by 34.1% in the first quarter. Millennium Management LLC now owns 422,066 shares of the company’s stock worth $5,373,000 after purchasing an additional 107,391 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Delcath Systems by 58.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 123,487 shares of the company’s stock worth $1,572,000 after buying an additional 45,695 shares during the period. JPMorgan Chase & Co. increased its holdings in Delcath Systems by 229.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 168,245 shares of the company’s stock worth $2,288,000 after buying an additional 117,118 shares during the period. Legal & General Group Plc purchased a new position in Delcath Systems during the 2nd quarter worth approximately $46,000. Finally, Rhumbline Advisers purchased a new position in Delcath Systems during the 2nd quarter worth approximately $586,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Stock Down 3.8%

Shares of DCTH traded down $0.51 during mid-day trading on Friday, hitting $13.01. 294,529 shares of the company traded hands, compared to its average volume of 448,454. The company has a market capitalization of $449.11 million, a PE ratio of 1,301.00 and a beta of 0.49. The business has a 50 day moving average of $11.68 and a 200 day moving average of $10.52. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $13.74.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Thursday, May 7th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.07. The company had revenue of $24.99 million during the quarter, compared to analysts’ expectations of $23.51 million. Delcath Systems had a net margin of 0.62% and a return on equity of 0.51%. As a group, research analysts expect that Delcath Systems will post -0.88 EPS for the current fiscal year.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.